Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia
Completed
Merck KGaA
Phase 1
MSC2490484A is an investigational drug that is being evaluated for the treatment of subjects
with advanced solid tumors or chronic lymphocytic leukemia (CLL) that likely differs from
other cancers in how it repairs damaged DNA (genetic material). This is a first-in-man Phase
I study, which means that it is the first time the study drug is being used in humans. The
main purpose is to determine the highest dose that does not cause unacceptable side effects.
The second is to determine the appropriate dose to use in future research for subjects with
cancer. Othergoals of the study are to learn about the drug's safety and side effects, how it
affects the tumor, and how the body processes the drug.
Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia
Completed
Merck KGaA, Darmstadt, Germany
Phase 1
MSC2490484A is an investigational drug that is being evaluated for the treatment of subjects
with advanced solid tumors or chronic lymphocytic leukemia (CLL) that likely differs from
other cancers in how it repairs damaged DNA (genetic material). This is a first-in-man Phase
I study, which means that it is the first time the study drug is being used in humans. The
main purpose is to determine the highest dose that does not cause unacceptable side effects.
The second is to determine the appropriate dose to use in future research for subjects with
cancer. Othergoals of the study are to learn about the drug's safety and side effects, how it
affects the tumor, and how the body processes the drug.
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Active, not recruiting
Merck KGaA
Phase 1
MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of
subjects with locally advanced tumors. The main purposes of this study are to determine the
safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and
in combination with chemoradiotherapy (Radiotherapy + cisplatin).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
